JP2023551481A5 - - Google Patents
Info
- Publication number
- JP2023551481A5 JP2023551481A5 JP2023532341A JP2023532341A JP2023551481A5 JP 2023551481 A5 JP2023551481 A5 JP 2023551481A5 JP 2023532341 A JP2023532341 A JP 2023532341A JP 2023532341 A JP2023532341 A JP 2023532341A JP 2023551481 A5 JP2023551481 A5 JP 2023551481A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- target
- sequence
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063119195P | 2020-11-30 | 2020-11-30 | |
| US63/119,195 | 2020-11-30 | ||
| PCT/US2021/061035 WO2022115715A1 (en) | 2020-11-30 | 2021-11-29 | Compositions and methods for selective depletion of target molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023551481A JP2023551481A (ja) | 2023-12-08 |
| JP2023551481A5 true JP2023551481A5 (https=) | 2024-12-09 |
Family
ID=81754931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023532341A Pending JP2023551481A (ja) | 2020-11-30 | 2021-11-29 | 標的分子の選択的枯渇のための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250195673A1 (https=) |
| EP (1) | EP4251130A4 (https=) |
| JP (1) | JP2023551481A (https=) |
| CN (1) | CN117279618A (https=) |
| AU (1) | AU2021386254A1 (https=) |
| CA (1) | CA3195315A1 (https=) |
| IL (1) | IL303152A (https=) |
| WO (1) | WO2022115715A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL303149A (en) * | 2020-11-30 | 2023-07-01 | Fred Hutchinson Cancer Center | Pd-l1 binding peptides and peptide complexes and methods of use thereof |
| WO2023235522A1 (en) * | 2022-06-02 | 2023-12-07 | Blaze Bioscience, Inc. | Compositions and methods for selective depletion of egfr target molecules |
| US20250372225A1 (en) * | 2022-06-13 | 2025-12-04 | Denali Therapeutics Inc. | A quantitative pharmacological model of enzyme replacement therapy |
| AU2023367846A1 (en) * | 2022-10-26 | 2025-05-01 | Amgen Inc. | Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases |
| EP4424703A1 (en) * | 2023-03-02 | 2024-09-04 | Amylonix AB | Polypeptides for transferrin receptor-mediated transcytosis |
| WO2025054465A1 (en) * | 2023-09-08 | 2025-03-13 | California Institute Of Technology | Compositions for transport of therapeutic cargos using miniprotein binders targeting ca-iv |
| WO2025076243A1 (en) * | 2023-10-03 | 2025-04-10 | Ionis Pharmaceuticals, Inc. | Cell-targeting complexes and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2512717A1 (en) * | 2003-01-09 | 2004-07-29 | Arizeke Pharmaceuticals Inc. | Compositions and methods for targeted biological delivery of molecular carriers |
| US8808697B2 (en) * | 2010-04-28 | 2014-08-19 | Oncoimmune, Inc. | Methods of use of soluble CD24 for therapy of rheumatoid arthritis |
| RU2013150331A (ru) * | 2011-04-20 | 2015-05-27 | Рош Гликарт Аг | СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА |
| LT3071597T (lt) * | 2013-11-21 | 2020-10-12 | F. Hoffmann-La Roche Ag | Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai |
| CN115925878A (zh) * | 2015-06-05 | 2023-04-07 | 艾比欧公司 | 用于治疗纤维化的内皮抑素片段和变体 |
| EP3773727A4 (en) * | 2018-04-09 | 2022-05-04 | Yale University | BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS |
| CA3120466A1 (en) * | 2018-12-14 | 2020-06-18 | Fred Hutchinson Cancer Research Center | Transferrin receptor targeting peptides |
-
2021
- 2021-11-29 CN CN202180089144.7A patent/CN117279618A/zh active Pending
- 2021-11-29 EP EP21899190.9A patent/EP4251130A4/en active Pending
- 2021-11-29 JP JP2023532341A patent/JP2023551481A/ja active Pending
- 2021-11-29 AU AU2021386254A patent/AU2021386254A1/en not_active Abandoned
- 2021-11-29 US US18/037,923 patent/US20250195673A1/en active Pending
- 2021-11-29 IL IL303152A patent/IL303152A/en unknown
- 2021-11-29 WO PCT/US2021/061035 patent/WO2022115715A1/en not_active Ceased
- 2021-11-29 CA CA3195315A patent/CA3195315A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023551481A5 (https=) | ||
| EP3844181B1 (en) | Multi-chain chimeric polypeptides and uses thereof | |
| JP7140861B2 (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| US20250002556A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| EP3844182B1 (en) | Single-chain and multi-chain chimeric polypeptides and uses thereof | |
| CN105492017B (zh) | 靶向经修饰的tnf家族成员 | |
| AU2018280683B2 (en) | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA | |
| AU2025200336A1 (en) | Single-chain chimeric polypeptides and uses thereof | |
| JP2024527293A (ja) | 持続放出免疫細胞結合型タンパク質および処置方法 | |
| CN116981470A (zh) | T细胞调节多肽和其使用方法 | |
| US20240294673A1 (en) | Recombinant proteinaceous binding molecules | |
| CN116964090A (zh) | 条件性双特异性结合蛋白 | |
| WO2024193635A1 (en) | Sirp variants and uses thereof | |
| KR20250067130A (ko) | Mage-a4 펩티드 이중 t 세포 연결체 | |
| KR20240169151A (ko) | 면역 세포 기능을 갖는, 항암제로서의 atp 의존성 작용제 | |
| Osaki et al. | Development of a bispecific antibody tetramerized through hetero‐associating peptides | |
| WO2025010272A1 (en) | Heterodimeric fc molecules and uses thereof | |
| WO2024094119A1 (zh) | 融合蛋白及其应用 | |
| CN119234000B (zh) | 可激活穿膜构建体和降解子 | |
| US20260116970A1 (en) | Novel sirp nanobodies | |
| Kang et al. | Immune cell engagers in lung cancer | |
| AU2024354387A1 (en) | Methods of generating, stimulating, or increasing proliferation of different subsets of cd8+ t cells | |
| WO2025096770A1 (en) | Multi-chain chimeric polypeptides and uses thereof | |
| Guo et al. | Nanobody-based targeted cancer therapy and immunotherapy: fear not the future | |
| Benmebarek | Characterization of bispecific antibodies that drive synthetic agonistic receptor-transduced T cells to mediate specific and conditional therapy in human pancreatic cancer models |